Introduction
Lower extremity peripheral artery disease (PAD) is a major health burden, representing the third-leading cause of cardiovascular morbidity related to atherosclerotic disease after coronary disease and stroke. The prevalence of PAD rises sharply with age, affecting almost 20% of the US population at the age of 80 [1, 2] . Epidemiologic studies have highlighted the global impact of the disease, suggesting dramatic recent increases in PAD prevalence in low and middle-income countries, and supporting the notion that we are faced with a global PAD pandemic, affecting more than 200 million men and women in both high-income countries and in the developing world [3] . Considering the mortality, morbidity and disability associated with PAD, there is an urgent need to develop new therapeutic strategies in order to prevent development and progression of the disease, and to treat life-threatening or limb-threatening complications. Experimental studies and early stage clinical trials have suggested that cell therapy may be a promising new approach for patients with PAD [4] . The current review manuscript discusses the potential role of cell therapy approaches in the treatment of PAD.
The pathophysiologic basis of PAD
The clinical manifestations of PAD reflect the consequences of a mismatch between blood supply and demand [5, 6] . The typical symptom of PAD is intermittent claudication, a characteristic squeezing leg pain associated with walking and relieved by rest. In normal subjects, exercise is associated with marked increases in peripheral artery blood flow and limb oxygen uptake, driven by increased metabolic demand. In contrast, in PAD patients, fixed stenotic lesions in peripheral arteries limit blood flow, reducing the supply of the affected territory and leading to ischemia. Although the main cause of supply and demand disequilibrium in PAD patients is structural, excessive vascular tone due to activation of neurohumoral pathways, or impaired vasodilatory responses due to endothelial dysfunction may increase vascular resistance, further limiting blood flow in the extremity [7] .
Repetitive limb ischemia followed by reperfusion causes mitochondrial dysfunction in skeletal myocytes and triggers generation of reactive oxygen species (ROS), leading to chronic structural changes in the skeletal muscle. ROSdriven apoptosis of skeletal myocytes leads to a reduction in skeletal muscle mass and is accompanied by fatty infiltration, impaired peripheral nerve function and fibrosis [8, 6, 9, 10] . These pathologic alterations are associated with chronic skeletal muscle dysfunction and significant functional impairment. In a subset of patients, chronic ischemia follows an aggressive clinical course that culminates in the development of rest pain and significant tissue loss, a condition termed critical limb ischemia (CLI). Traditional treatment strategies in patients with CLI are focused on surgical bypass or endovascular interventions, aimed at restoring perfusion to prevent amputation of the affected limb [11] . However, a significant percentage of CLI patients do not have revascularization options; these patients have poor prognosis and often require amputation.
Cell therapy as a therapeutic approach in PAD
Considering the limited treatment options for patients with severe PAD, the rationale for cell therapy approaches is sound. In patients with severe atherosclerotic disease of the native arterial circulation, administration of cell populations capable of activating an angiogenic program may result in formation of neovessels, improving perfusion of the affected limb. Increased blood supply may prevent ischemic episodes and may even contribute to restoration of normal skeletal muscle structure. It should be emphasized that any beneficial effects of cell therapy in PAD may not be necessarily due to incorporation of the cells into the vascular network, but may involve paracrine effects mediated through secretion of angiogenic mediators. Cell therapy may also activate yet unidentified cytoprotective and regenerative pathways that may improve limb function through effects independent of neovessel formation.
A growing body of experimental and clinical evidence suggests that cell-based therapy may hold promise in patients with severe PAD. Experimental investigations have used models of hindlimb ischemia to study the effectiveness of cell therapy approaches in promoting angiogenesis and in attenuating skeletal muscle injury. On the other hand most clinical studies investigating the effectiveness of cell therapy in patients with CLI are small phase I or II clinical trials. Considering the variable approaches used by different groups, the wide range of cell types used, and the absence of standardized protocols for characterization of the cells and for evaluation of clinical outcome, there is substantial uncertainty regarding the effectiveness of various cell types in PAD patients.
The therapeutic potential of endothelial progenitor cells (EPCs)
The identification of EPCs, as bone marrow-derived progenitors, that home to sites of injury and may contribute to angiogenesis [12] provided a strong rationale for the use of cell therapy in PAD patients. It should be noted that, despite progress in understanding the mechanistic basis of the angiogenic response, the contribution of blood-derived progenitors in neovessel formation following injury remains controversial. In a mouse model of hindlimb ischemia, both marrow-derived and non-marrow derived endothelial progenitor populations have been implicated in formation of neovessels [13] . Despite the recent use of lineage tracing approaches in mouse models, the origin of neovascular endothelial cells in sites of injury remains controversial. Studies in the ischemic myocardium suggested a significant contribution of mesenchymal cells that undergo conversion into endothelial cells through a p53-dependent mechanism [14] . In contrast, other investigations suggested that practically all neovessels in the injured myocardium are derived from pre-existing endothelial cells, and not through lineage transdifferentiation [15] . It is plausible that the relative contributions of various cellular sources in the angiogenic response may be dependent on the pathophysiologic context and on the site of injury. Unfortunately, lineage tracing studies investigating the cellular origin of angiogenic vascular cells in ischemic skeletal muscle have not been performed.
Regardless of the origin of endogenous angiogenic endothelial cells in the ischemic limb, local injection of circulating endothelial progenitors would be expected to enrich the ischemic site with a pool of angiogenic cells, promoting neovessel formation and improving function. To achieve this goal, several different approaches have been used, injecting unselected or marker-specific mononuclear cells from the bone marrow, or the peripheral blood. These populations may contain a subset of bona fide endothelial progenitors that incorporate to the vascular network forming new vessels, and other cell types that may contribute to the angiogenic process by secreting cytokines, angiogenic growth factors, matrix metalloproteinases, matricellular proteins, or miRNA-containing exosomes ( Figure 1 ) [16 ,17,18] .
Bone marrow-derived mononuclear cells (BM-MNC) and peripheral blood-derived mononuclear cells (PB-MNC) in the treatment of PAD
Unselected mononuclear cells harvested, derived either from the bone marrow or the peripheral blood, represent a mixture of monocytes, non-hematopoietic stromal cells (including mesenchymal stem cells), and EPCs and have been used in both experimental models of limb ischemia and in patients with PAD. In the TACT (Therapeutic Angiogenesis using Cell Transplantation) study, injection with autologous BM-MNCs in the gastrocnemius of the ischemic limb reduced rest pain and increased transcutaneous oxygen pressure in patients with CLI; improvement was sustained for at least 24 weeks [19] . Over the last few years, several additional clinical trials suggested that intramuscular or intra-arterial injections of BMMNCs or PB-MNCs in patients with CLI are safe, and may reduce rest pain and improve ulcer healing (Table 1 ) [20, 21] . In many studies, improved clinical outcome was associated with objective evidence of enhanced perfusion. However, in most studies, effects on amputation rates did not reach statistical significance. Some of the larger, more rigorous, and well-designed studies failed to support the beneficial effects [22 ] , suggested by smaller nonplacebo controlled investigations [20] . The conflicting findings may reflect the clinical improvement observed in placebo-treated patients [22 ] , and emphasize the importance of rigorous design, large population size and accurate blinding in order to test the effectiveness of therapy. The optimal cell type, concentration of cells and route of delivery remain unclear. Moreover the mechanistic basis for any protective effects remains obscure. Prolonged survival of the injected cells in the hostile environment of the ischemic limb has not been documented. Thus, it is unclear whether any benefit related to cell therapy is due to direct involvement of the cells in angiogenesis, or reflects paracrine effects that may include indirect stimulation of angiogenic pathways, modulation of inflammatory cascades, or cytoprotective actions on the ischemic limb.
Administration of marker-specific cells
Considering the functional and phenotypic heterogeneity of MNCs, identification of specific MNC subsets with angiogenic or cytoprotective properties represents a rational approach for further development of cell therapy strategies for PAD patients. Evidence suggests that CD34 may mark a subset of cells with angiogenic potential; a subset of CD34+ cells may be capable of differentiation to mature endothelial cells. In a randomized controlled pilot study, intramuscular injection of Granulocyte-Colony Stimulating Factor (G-CSF)-mobilized CD34+ cells in patients with CLI was safe and was associated with trends towards reduced amputation rates [23] . Strategies using multicellular subsets of bone marrow-derived cells have also been tested. Ixmyelocel-T is an expanded population of bone marrow cells comprised predominantly of CD90+ mesenchymal cells and a subset of bone marrow macrophages. In a randomized phase 2 trial in patients with CLI, treatment with Ixmyelocel-T was safe, but did not significantly affect major amputation rates [24] . Expression of high levels of the cytosolic enzyme aldehyde dehydrogenase (ALDH) has also been used to select a subset of angiogenic progenitors derived from bone marrow cells. In a randomized double-blind phase 2 clinical trial, intramuscular injection of cells with high ALDH activity did not improve peak walking time and perfusion in patients with claudication [25 ] .
Mesenchymal stem cells (MSC)
Because of their potential for transdifferentiation and their potent effects in modulation of cell survival, inflammation and angiogenesis, MSCs are promising candidates for PAD cell therapy. A randomized controlled trial showed that infusion of autologous bone marrow-derived MSCs (BM-MSC) improved symptoms, accelerated ulcer healing and accentuated collateral blood vessel growth in diabetic patients with CLI [21] . Moreover, administration of allogeneic bone marrow-derived MSCs from healthy donors in patients with end-stage PAD was safe and well- 3 mo-2 y Cell therapy reduced AR (major amputations in the treatment group: 0% at 3 mo and 30% at 2 y and in the control group 60% at 3 mo and 2 y), increased ABI at 3 mo and 2 y, and increased TcO 2 .
[40]
Autologous CD133+ cells sorted from G-CSF-mobilized PB-MNCs 10 patients (2:1 randomization) Gender: 8M, 2W. Mean age: control 85 y, treatment 65 y.
mo
Subject enrollment was suspended due to a high rate of mobilization failure. Cell therapy was associated with non-significant trends towards lower AR (control: 66%, treatment: 14%), reduced walking impairment and improved quality of life [41] Autologous BM-MNCs (im) 25 patients (treatment group n = 13, control n = 12). Age: treatment 62y, control 68 y. [ 21] tolerated, but did not have significant effects on amputation rates [26] .
Appraisal of the clinical evidence on the effects of cell therapy in PAD
A recent meta-analysis of randomized, nonrandomized and noncontrolled studies for treatment of PAD suggested that although cell therapy did not affect all-cause mortality, it may have significantly improved the chances of amputationfree survival and ameliorated endpoints related to limb perfusion, pain and functional capacity in comparison with control treatment [27 ] . However, efficacy of cell therapy on all endpoints was no longer significant in placebo-controlled studies and disappeared in randomized controlled trials with a low risk of bias [27 ] . Thus, there is currently no robust evidence to support the effectiveness of cell therapy in patients with PAD.
PAD patients who are not candidates for revascularization strategies due to high risk, unfavorable vascular involvement, or failed endovascular approaches (no-option patients) represent a major therapeutic challenge and have a poor prognosis. It has been argued that, because there is no alternative to amputation in patients with endstage CLI, cell therapy should be administered if available, even in the absence of robust evidence to support effects on amputation-free survival [27 ,4] . However, implementation of expensive treatment strategies with minimal or no benefit to the affected patient population is of limited value, and may be harmful by reallocating healthcare resources, depriving other patient populations from highly effective therapies.
What are the reasons for the limited success of cell therapy in PAD patients? First, design of cell therapy approaches has Cell therapy for peripheral artery disease Frangogiannis 31 3 mo Cell therapy did not significantly affect AR (treatment 21%, control 5%) and did not significantly increase ABI. However, cell therapy improved ulcer healing and reduced rest pain.
[46]
Autologous BM-MNCs (im)+ VEGF gene therapy 32 non-diabetic patients. Treatment: n = 16, 11M 5W, mean age 66.8 y. Control: n = 16, 10M, 6W, mean age 68.3 y.
mo
No statistically significant difference in AR between groups (treatment: 25%, control: 50%). Only patients enrolled in the treatment group exhibited increased ABI (75% of treated patients) and ulcer healing (69% of treated patients).
[47]
Autologous BM-MNCs (im) 58 patients BM-MNC: (n = 29, 22M, 7F), Placebo: (n = 29, 23M, 6F). Diabetes: treatment 44.8%, control 41.4%. Mean age: treatment 61 y, control 63 y.
6 mo Cell therapy improved rest pain and ulcer healing and increased ABI. There was no significant difference in the rate of major amputations (treatment 10%, control 17%).
[48]
Autologous expanded BM-MNCs, containing CD90+ cells and a subset of macrophages (Ixmyelocel-T) 72 patients Treatment: n = 48, 34M 14F. Control: n = 24 14M 10F. Diabetes: treatment 44%, control 63%. Age: treatment 69.2 y, control 67.3 y.
12 mo Cell therapy was well-tolerated, but did not affect AR (control: 25%, treatment 21%).
[24]
Repetitive (3 times in a 3-week interval) autologous BM-MNC (ia) 160 patients. Treatment: n = 81 (57M, 24F), control: n = 79, (51M 28F). Age: treatment 69 y, control 65 y. Diabetes: treatment 36%, control 39%.
Cell therapy had no effects on AR (control 13%, treatment 19%), rest pain, ABI and TcO 2 .
[22 ]
Autologous BM-MNC (im) 38 patients (treatment n = 18, placebo n = 20). Diabetes: treatment 55%, control 35%.
6-12 mo
Cell therapy has no effects on AR (placebo: 26%, treatment: 18%). Cell therapy and control groups had comparable improvements in rest pain and in TcO 2 .
[49]
Allogeneic expanded BM-MSC derived from healthy donors (im) 20 patients. MSC group (n = 10), placebo (n = 10) Patients had either atherosclerotic disease or thrombangitis obliterans 6 mo Cell therapy was safe and increased ABI. There were no significant effects on AR.
[26]
Allogeneic expanded BM-MSC derived from healthy donors (high and low dose groups -im)
90 patients with CLI due to thrombangitis obliterans. Control (n = 18), low dose (n = 36), high dose (n = 36). Age range: 38-42 y. There is little doubt that cell therapy in PAD treatment has a bright future. To achieve the full potential of this highly promising strategy, there is a need for a concerted effort to advance our knowledge on the fundamental cellular mechanisms of angiogenesis, while investing in robust clinical studies to test the most promising strategies in PAD patients.
Conclusions and future directions
The need for randomized double-blind placebo controlled studies to document any effects of cell therapy approaches in PAD patients cannot be overemphasized. The improvement observed in placebo-treated patients in PAD clinical trials [22 ,28] emphasizes the need for rigorously designed and well-controlled studies in order to derive robust conclusions. Moreover, interpretation of the findings of clinical trials is dependent on introduction of endpoints for assessment of the cell biological consequences of the strategy. Assessment of cell homing and survival, and quantitative analysis of the effects of therapy on the vasculature in the ischemic area can provide critical information to understand the basis for success or failure, and to identify patient subpopulations with favorable responses.
Most importantly, we need to introduce new cell biological concepts in the design of cell therapy approaches. Dissection of the cell biological mechanisms of angiogenesis is critical to design an effective cell therapy approach for PAD patients. Understanding the phenotypic profile, properties, and mobilization mechanisms of endothelial progenitor populations and of mononuclear cell subsets with angiogenic properties is needed to define optimal cell types for therapy. Moreover, treatment with mediators that improve mobilization, homing and survival of endogenous progenitor cells may be useful to maximize benefit of cell therapy.
Chemokines are a family of chemotactic cytokines with an important role in leukocyte trafficking following ischemia [29] . Several members of the chemokine family play essential roles in mobilization and migration of endogenous EPCs and may regulate their recruitment in ischemic sites [30, 31] . Accentuation of chemokine signaling may be a promising strategy to enhance infiltration of the ischemic tissue with angiogenic cells. The CXC chemokine Stromal cell-derived factor (SDF)-1/CXCL12 is a key regulator of bone marrow cell mobilization and is critically involved in recruitment of progenitor cells in ischemic tissues [32, 33] . It has been suggested that in certain pathologic conditions, such as diabetes, hyperglycemia-mediated downmodulation of chemokine receptor expression in EPCs and other progenitor cells may reduce their homing in sites of injury, resulting in defective angiogenesis and impaired reparative responses. A recent study demonstrated that manipulation of EPCs to increase expression of the chemokine receptor CXCR7 (one of the receptors that mediate CXCL12 actions) improved outcome in a model of limb ischemia in diabetic mice, enhancing the angiogenic function of the cells [34 ] . Other membersofthechemokinefamilymayactindirectly,increasing the angiogenic capacity of MNCs. The CX3C chemokine Fractalkine/CX3CL1 has been suggested to increase angiogenic potential of bone marrow-derived macrophages by accentuating expression of platelet factor-4/CXCL4 [35] . Pre-treatment of MNCs with mediators inducing an angiogenic program may stimulate their therapeutic potential in PAD. Moreover, genetic manipulations activating a prosurvival program in EPCs [36] or incorporation of matrix substrates that prolong survival and promote differentiation [37] may accentuate the beneficial actions of cell therapy.
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